Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405567 | 0.87 | TP53 (0.32) | HSD17B2TP53 | |
| SCHEMBL5422363 | 0.86 | HSD17B2 (0.30) | HSD17B2 | |
| SCHEMBL5417417 | 0.80 | ESR1 (0.31) | KDM4E | |
| SCHEMBL5405637 | 0.79 | MAOB (0.33) | TP53MAPTMAOBMAOAKDM4E | |
| SCHEMBL5408325 | 0.77 | RIPK1 (0.31) | TSHRGAA | |
| SCHEMBL5405585 | 0.77 | MAOB (0.32) | TP53MAPTMAOBMAOAKDM4E | |
| SCHEMBL2270881 | 0.68 | KDM4E (0.42) | TP53MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL5417634 | 0.61 | — | — | |
| SCHEMBL27368422 | 0.57 | ACHE (0.46) | MAPTMAOBMAOAHTR2CALDH1A1 | |
| SCHEMBL343187 | 0.57 | ACHE (0.50) | EPHX1TP53KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362049-B1 | PYRAZOLO-TRIAZOLES AND USE OF SAID COMPOUNDS FOR DYEING KERATINOUS FIBRES | OREAL (FR) | 2006-06-21 | — | — | EP | claimed |
| US-20040088801-A1 | Novel pyrazolo-triazoles and use of said compounds for dyeing keratinous fibres | L'OREAL S.A. (FR) | 2004-05-13 | — | — | US | claimed |
| EP-1362049-A1 | NOVEL PYRAZOLO-TRIAZOLES AND USE OF SAID COMPOUNDS FOR DYEING KERATINOUS FIBRES | L'OREAL (FR) | 2003-11-19 | — | — | EP | claimed |
| WO-2002064596-A1 | NOVEL PYRAZOLO-TRIAZOLES AND USE OF SAID COMPOUNDS FOR DYEING KERATINOUS FIBRES | L'OREAL (FR) | 2002-08-22 | — | — | WO | claimed |
| US-7192452-B2 | Pyrazolo-triazoles and use of said compounds for dyeing keratinous fibres | L'OREAL S.A. (FR) | 2007-03-20 | — | — | US | disclosed |
| EP-1362049-B1 | PYRAZOLO-TRIAZOLES AND USE OF SAID COMPOUNDS FOR DYEING KERATINOUS FIBRES | OREAL (FR) | 2006-06-21 | — | — | EP | disclosed |
| US-20040088801-A1 | Novel pyrazolo-triazoles and use of said compounds for dyeing keratinous fibres | L'OREAL S.A. (FR) | 2004-05-13 | — | — | US | disclosed |
| EP-1362049-A1 | NOVEL PYRAZOLO-TRIAZOLES AND USE OF SAID COMPOUNDS FOR DYEING KERATINOUS FIBRES | L'OREAL (FR) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002064596-A1 | NOVEL PYRAZOLO-TRIAZOLES AND USE OF SAID COMPOUNDS FOR DYEING KERATINOUS FIBRES | L'OREAL (FR) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040088801-A1 | Novel pyrazolo-triazoles and use of said compounds for dyeing keratinous fibres | KRT18, CYC1, CBR3 | EPHX1 2960/4885HSD17B2 801/4885TP53 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.